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Problem Definition
• ESRD patients are vulnerable to
hypoglycemia due to impaired insulin
clearance, glucose metabolism changes,
and effects of dialysis. Hypoglycemic
events lead to serious and life-
threatening complications.
Aims For Improvement
• To decrease the rate of hypoglycemic
events amongst ESRD patients receiving
insulin for hyperkalemia treatment.
Methods
• Retrospective review on the rates of
hypoglycemic events amongst ESRD
patients before (Pre-Intervention)
and after (ESRD protocol) the
introduction of 'ESRD dosing' order set
on November 19, 2019.
• Pre-Intervention and standard
protocol groups received 10 units IV
regular insulin for all patients regardless
of kidney function, while ESRD protocol
patients received 5 units of IV regular
insulin.
Results
Lessons Learned and 
next steps
• This study shows that hypoglycemia is a
common occurrence following the use
of IV insulin for management of
hyperkalemia despite concurrent use of
glucose.
• With this intervention, the number of
ESRD patients receiving appropriate
insulin therapy was increased, and there
was a significant reduction in
hypoglycemia
• We also noticed there was a reduction in
the rate of hypoglycemia in non ESRD
patients as well. Other factors may be
involved that we have not identified.
• We hypothesize, likely ESRD dosing for
CKD patients can also lower
hypoglycemic events
• Limitation – We only focused
on patients who were treated
with the order set.
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• Hypoglycemia was defined as BG <70 mg/dl and we included any hypoglycemic
events within 6 hours of receiving Insulin for hyperkalemia treatment
• Among the patients who received pre-intervention insulin protocol, hypoglycemia rate
was noted to be 51.5 % (17/33) as opposed to 17.6% (6/34) in ESRD protocol group.
